In conclusion, carboplatin AUC5 can provide a comparable cytotoxic effect to carboplatin AUC6 in patients with HER2+ breast cancer receiving six cycles of neoadjuvant TCHP, with fewer complications associated with clinically meaningful anaemia. This evidence concerns the gene ERBB2 and anemia (phenotype).